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Abstract
Background: Nasal and extra nasal carriage of methicillin-resistant S. aureus (MRSA) is a pre-existing condition that
often leads to invasive MRSA infection, as MRSA colonization is associated with a high risk of acquiring MRSA
infection during hospital stays. Decolonization may reduce the risk of meticillin-resistant Staphylococcus aureus
(MRSA) infection in individual carriers and prevent transmission to other patients.
Methods: A retrospective cohort study was conducted to evaluate the effectiveness of two decolonization protocols
for newly diagnosed MRSA carriage in hospitalized patients and to assess the impact of decolonization on the rate of
MRSA infection. The study population consisted of all patients diagnosed as MRSA-positive between January 2006 and
June 2010.
Patients diagnosed as carriers were designated as requiring contact precautions by the hospital infection control team.
The standing order protocol of the hospital pertaining to decolonization procedures was then applied, and all newly
diagnosed patients were administered one of the two decolonization treatments outlined in the hospital protocol, with
the exception of MRSA respiratory carriers (MRSA obtained from sputum or other lower respiratory tract samples). The
two decolonization treatments consisted of the application of intranasal mupirocin 2 % and washing with chlorhexidine
soap (40 mg/mL) (mupi/CHX) or application of intranasal povidone-iodine and washing with povidone-iodine soap (PVPI),
with each treatment lasting for 5 days.
Success was determined by at least three successive nose swabs and throat and other screened site swabs that tested
negative for MRSA before patient discharge.
Results: A total of 1150 patients admitted to the hospital were found to be infected or colonized with MRSA. Of the
1150 patients, 268 were prescribed decolonization treatment. 104 out of 268 patients (39 %) were successfully
decolonized. There was no significant success after two decolonization failures.
MRSA infection rate among the successes and failures were 0.0 and 4.3 %, respectively [P = 0.04].
Conclusions: Our results fit well with the prescription of decolonization based on local strategy protocols but
reflect a low rate of successful treatment.
Although the success rate of decolonization was not high in our study, the effectiveness of decolonization on the
infection rate, justifies the continuation of this strategy, even if a marginal cost is incurred.
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Background
The burden of methicillin-resistant Staphylococcus aureus
(MRSA) infection remains high, with approximately 100
000 invasive MRSA infections occurring annually in the
United States causing approximately 19 000 deaths— more
than that caused by HIV, for example [1]. Moreover, treat-
ment options for MRSA are limited, most often require
intravenous access, have greater side effects and are more
expensive than standard treatments [2].
Nasal and extra nasal carriage of methicillin-resistant
S. aureus (MRSA) often leads to invasive MRSA infec-
tion, as MRSA colonization is associated with a risk of
up to 30 % of acquiring MRSA infection during hospital
stays [3, 4]. Moreover, carriers of MRSA serve as reser-
voirs in hospitals and long-term care facilities, and the
pressure of colonization plays an important role in the
subsequent dissemination of MRSA strains in these in-
stitutions [5].
In contrast to other resistant or difficult to treat mi-
croorganisms, MRSA carriage can be eliminated through
the application of decolonization agents, such as nasal
mupirocin and chlorexhidine soap. Several prospective
studies have shown that the optimization of carriage
eradication can be effective in controlling MRSA dis-
semination [6, 7]. A randomized controlled double blind
trial showed that The MRSA eradication was 25 % in the
mupirocin group in comparison with placebo. The re-
sults suggest that nasal mupirocin is only marginally ef-
fective in the eradication of multisite MRSA carriage in
a setting where MRSA is endemic [8].
It appers from a metanalysis that there is insufficient
evidence to support use of topical or systemic antimicro-
bial nasal or extra-nasal MRSA. There is no demon-
strated superiority of either or systemic therapy, or a
combination of these agents [9].
Little is known, however, about the rate of success of
decolonization strategies under real-life conditions. More-
over, many unresolved issues remain, including the num-
ber of unsuccessful eradication attempts that should be
administered before concluding failure or the collateral
benefit of such decolonization procedures, even if unsuc-
cessful, on reducing infection rates.
Objective
The aim of this study is to evaluate the effectiveness of
two decolonization protocols for newly diagnosed MRSA
colonization in hospitalized patients and to assess the
impact of decolonization on the rate of MRSA infection.
Methods
Setting
Erasme Hospital is the 864-bed academic hospital of the
Université Libre de Bruxelles (Brussels, Belgium). The
hospital admits, on average, 30,000 patients annually. An
MRSA surveillance and control program was initiated in
the hospital in 1990 and continues presently in accord-
ance with national guidelines.
Screening for MRSA via swabbing of nose and throat
completed by wounds swabbing is routinely performed for
patients with a previous history of MRSA colonization or
who harbor one of more of the following conditions:
patients who have been previously hospitalized or under-
gone antibiotic treatment within the past six months, pa-
tients admitted from other hospitals or long-term care
facilities, and patients with wounds, skin lesions or foreign
material. Screening is performed twice weekly in patients
in intensive care units. MRSA decolonization is offered
for a maximum number of patients for both the control of
dissemination and to reduce the rate of infection.
Study design and definitions
A retrospective cohort study was conducted to assess
the efficacy of MRSA decolonization and to evaluate the
impact of two decolonization protocols on the rate of
MRSA infection in patients newly diagnosed as colo-
nized with MRSA. Patients diagnosed as colonized were
designated as requiring contact precautions by the hos-
pital infection control team. The standing order protocol
of the hospital pertaining to decolonization procedures
was then applied, and all newly diagnosed patients were
administered a decolonization treatment outlined in the
hospital protocol, with the exception of MRSA respira-
tory carriers (i.e., MRSA obtained from sputum or other
lower respiratory tract samples). The two decolonization
treatments consisted of the application of intranasal
mupirocin 2 % and washing with chlorhexidine soap
(40 mg/mL) (mupi/CHX) or application of intranasal
povidone-iodine and washing with povidone-iodine soap
(PVPI), with each treatment lasting for 5 days. Mupi/
CHX was used for uncomplicated cases, whereas PVPI
was used for more complicated cases, as defined in Fig. 1.
Patients who failed to respond to two mupi/CHX fail-
ures were then treated with PVPI. Success was deter-
mined by at least three successive nose swabs and throat
and other screened site swabs that tested negative for
MRSA before the patient could be discharged from the
hospital. There was at least 48 h between each swab.
Study population
The study population consisted of all patients diagnosed as
MRSA-positive between January 2006 and June 2010. Infor-
mation collected included demographic characteristics,
transfer(s) from another hospital or long-term care facility,
antibiotic use, co-morbidities, site(s) of colonization or in-
fection, date(s) of first colonization, date and decolonization
treatment, effectiveness of decolonization procedures, sub-
sequent re-occurrence of MRSA infection, date and site of
infection (if any) and date of discharge from the hospital.
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Patients for whom a decolonization treatment was not pre-
scribed were classified in the no treatment group.
MRSA identification
Swabs were plated separately onto selective chromogenic
MRSA agar (chromID MRSA medium, bioMérieux, Marcy
l’Etoile, France) and inoculated into brain–heart infusion
broth (BHIB) supplemented with 7.5 % NaCl, and then
stored at 4 °C for further analysis. Samples were incubated
overnight, and then, the BHIB was subcultured onto chro-
mID MRSA agar. Selective plates were incubated at 35 °C
for 48 h and examined daily. Suspected MRSA colonies
were identified by the coagulase test using human plasma.
Resistance to oxacillin was determined via the cefoxitin
disk diffusion method (BD, Oxoid, UK) according to
Clinical and Laboratory Standards Institute (CLSI)
recommendations. Staphylococcal Cassette Chromosome
mec (SCCmec) presence were determined by PCR.
Statistical analysis
Statistical analysis was performed using Epi Info™ 7 (Cen-
ters for Disease Control and Prevention, Atlanta, GA,
USA). Normally distributed continuous variables were
compared using a 2‐sample t test, while categorical data
were compared using a χ2 test with a Yates correction.
Results
A total of 1150 patients admitted to the hospital (0.8 % of
admissions) were found to be infected or colonized with
MRSA over the study period (2006–2010). Of these,
MRSA carriage was determined to be imported in 67 %
Fig. 1 Routine MRSA decolonization protocols employed during the study
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(772) of the patients and hospital-acquired in 33 % (378)
of the patients.
Of the 1150 patients, 708 were excluded from the
study because of incomplete follow-up for one of more
of the following reasons: 335 were excluded before the
decolonization treatment was implemented due to pa-
tient death (43) or because they were earlier discharged
from the hospital (292), while 373 were deemed inevalu-
able because their hospital stay was too short for the
decolonization treatment to be completed and evaluated
(328 of the 373), patient death during this period (34 of
the 373), or for other reasons (11 of the 373).
Complete follow-up data were available for 442 pa-
tients screened by infection control nurses and consid-
ered eligible for decolonization treatment (Table 1).
However, decolonization treatment was not proposed for
174 (39 %) of these patients because they did not meet
one or more of the local-protocol inclusion criteria.
Of the 268 patients who were prescribed decolonization
treatment (Fig. 2), 34 % (90/268) were cleared of MRSA in-
fection at the first attempt and 20 % (14/72) at the second
attempt, but no successful decolonization was achieved at
the third or fourth attempt. One patient went from the
uncomplicated cases protocol to the complicated cases
protocol after two failures with mup/CHX treatment.
Overall, 104 out of 268 patients (39 %) were success-
fully decolonized, whereas 164 were not (Fig. 2). The
success rates of mupi/CHX and PVPI in the first treat-
ment attempt were 51 and 18 %, respectively, and 29
and 16 % in the second attempt, respectively.
The success rates of mupi/CHX and PVPI were, re-
spectively, 56 and 23 % (Fig. 3).
Among the 104 patients who were successfully decolo-
nized, 53 were re-admitted after a median period of
162 days, with 50 out of the 53 (94 %) still testing nega-
tive for MRSA carriage at the time of re-admission.
Outside our cohort, among the 328 patients who were
prescribed decolonization with incomplete follow-up, 109
had at least one (85) or two (24) negative screenings
for MRSA, with 185 out of these 328 patients being
subsequently re-admitted to the hospital; of these indi-
viduals, 111 were negative for MRSA at the time of re-
Table 1 Characteristics of patients with methicillin-resistant Staphylococcus aureus eligible for decolonization between January 2006
and June 2010 (n = 442)
Proportion of patients
Patients treated Patients not treated P
(n = 268) (n = 174)
Sex Male 142 (53) 104 (60) .160
Female 126 (47) 70 (40)
Age, mean, years ± SD 69.09 ± 16.52 69 ± 17.26 .9
Length of hospital stay mean, years ± SD 48.54 ± 35.71 36.91 ± 32.99 <.001
Type of MRSA colonization
Nosocomial 107 (39.9) 88 (50) .04
Site of colonization
Nose 147 (55) 53 (26.5) <.001
Throat 115 (43) 43 (25) <.001
Perineum 116 (43) 39 (25) <.001
Others 109 (41) 146 (84) <.001
Wound 85 (31.7) 46 (26.4) .2
Number of colonized sites
Mean, no ± SD 1.8 ± 1 1.6 ± 0.94 .03
≥2sites 128 (47.8) 64 (36.8) .02
Comorbidity (underlying condition)
Immunosuppressive therapy 36 (13.4) 39 (52) .01
Diabetes 71 (65) 38 (35) .26
Urine catheter 14 (5.2) 6 (3.4) .48
Dialysis 11 (4.1) 4 (2.3) .30
CVC 9 (3.3) 10 (5.7) .22
COPD 31 (11.5) 33 (18.9) .003
Note: data are no (%) of patients
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admission, while 65 were positive and 9 were not
screened.
If we consider these final 111/185 patients as deconta-
minated with success (even if not at the time of first dis-
charge) and add them to the 104/268 successfully
treated at discharge, the rate of successful decolonization
is approximately 47 % (215/453 patients).
Subsequent MRSA infection rate among the suc-
cesses and failures were 0.0 and 4.8 % (8/164), respect-
ively [P = 0.04]. The median (range) time period (days)
from the end of treatment to infection were 43.50 (range:
2–258). Five out of 8 infected patients had been treated
with the PVPI treatment and three out of 8 infected pa-
tient with the MUPI/CHX treatment.
MRSA infection rate among patients for whom
decolonization treatment was unsuccessful and among pa-
tients initially excluded from decolonization treatment
were 4.3 and 20 %, respectively [P < 0.0001]).
Discussion
Eradication of MRSA carriage is a crucial clinical chal-
lenge, as it was demonstrated to reduce the risk of infec-
tion in MRSA-colonized patients and prevent MRSA
cross-transmission to patients who were non-colonized.
The efficacy of MRSA decolonization treatment remains
controversial, however [10, 11]. The success rate re-
ported in prospective trials ranged from as low as 25 %
to as high as 95 % depending on the treatment used and
the inclusion criteria [12–15]. Our results show that
among an unselected population of patients without re-
spiratory MRSA carriage, only one-third were success-
fully decolonized after the first treatment, while 39 %
were decolonized following two attempts, with no fur-
ther success obtained beyond two previous failures. With
one exception [12], the overall success rate of MRSA
decolonization in our study seems to be lower than
those of other published studies [6, 16–21], one study
has approximatively the same success rate and included
outpatients with skin problems [22]. The success rates of
mupi/CHX and PVPI in the first treatment attempt were
51 and 18 %, respectively, 29 and 16 % in the second at-
tempt, respectively. The success rates of mupi/CHX and
PVPI were, respectively, 56 and 23 % but PVPI use was
restricted to complicated cases (Fig. 3).
However, by comparison with others, we included
more patients with less-than-ideal prognostic factors,
Fig. 2 Decolonization results
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such as those with chronic wounds. Indeed, one-third of
our patients had skin lesions, which are considered to be a
contraindication for eradication measures in several stud-
ies [14, 19] and may have contributed to the comparatively
low success rate. When considering only patients with
carriage limited to nasal cavities, efficacy of decolonization
appears significantly higher (73 %) and more in line with
the range found in other studies in the literature. In
addition, because of the relatively short length of hospital
stay, we were unable to evaluate treatment success in
many patients, which further contributes to our lower suc-
cess rate. Our data highlight the gap that exists between
controlled studies and real-life situations with many fac-
tors contributing to this difference.
Beyond the poor prognosis factors and the underestima-
tion due to patients discharged from the hospital before
completion of the decolonization protocol or follow-up
screening, our data were also negatively impacted by our
decision to reject patients for whom the hospital stay was
shorter than the five days needed for decolonization. We
most likely could treat a much higher number of patients
by treating all concerned carriers regardless of their sched-
uled length of stay. The efficacy of the decolonization
protocol would also be enhanced through the inclusion of
oral mouth CHX solution and hair shampoo treatments
and by measuring compliance to the prescribed schedule
of the nurses charged with administering the protocol.
Although we observed a much lower efficacy of treat-
ment with PVPI than with mupi/CHX in eradicating
MRSA occurrence, patients who received the two treat-
ments differed considerably in terms of their risk of fail-
ure. Thus, the question of what constitutes the best
Fig. 3 Decolonization results among the two protocols
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choice of topical MRSA decolonization treatment re-
mains unresolved. We continue to avoid the use of
mupirocin in patients with high levels of colonization
because of the well-documented occurrence of resistance
associated with the frequent use of mupirocin.
The rate of MRSA infection was found to be lower
even in patients who were treated without success than
in untreated patients. We should also highlight that pa-
tients excluded from decolonization (174 patients) have
a high infection risk. Attempted decolonization would
thus seem to be at least a somewhat effective approach
for reducing MRSA infection even in patients without
effective eradication. Because of this, we recommend
that systematic topical decolonization in MRSA carriers
be undertaken, in accordance with recent proposals
made by other researchers [13].
Five factors were associated with a high risk of failure
of the decolonization treatment: presence of wounds,
presence of more than 2 colonized sites, other situations
than only being positive for MRSA by nasal swab, and
where MRSA resistance to mupirocin was high (Table 2).
The following clinical conditions did not affect the
decolonization rate: diabetes, immunosuppressive ther-
apy, presence of a urinary catheter, dialysis, COPD, or
presence of a central venous catheter.
Conclusion
Our results fit well with the prescription of decolonization
based on local strategy protocols but reflect a low rate of
successful treatment compared to that of other studies in
the literature. This may reflect differences in prevalence of
failure risk factors compared with our population. To im-
prove the results of decolonization, we suggest to ensure
compliance of the nursing and medical staff to the care
protocol (not assessed in our study) and that an oral
decolonization component should be added to the
decolonization procedures. In addition, the MRSA in-
fection rate differed significantly between the group of
patients successfully decolonized and those who were
not and even between the instance of unsuccessful
decolonization and patients who were not infected
with MRSA.
Finally, although the success rate of decolonization was
not high in our study, the effectiveness of decolonization
on the infection rate, justifies the continuation of this
strategy, even if a marginal cost is incurred.
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